OXERVATE® CASE EXCHANGE
A problem-based learning program

On behalf of Dompé and Dr. Timothy J Poirier, we invite you to join us for OXERVATE® Case Exchange, an interactive, problem- based learning promotional program.

This small-group forum will provide an opportunity for an open and real-world discussion around a hypothetical patient case, facilitated by Dr. Poirier.

Don't miss this unique opportunity for a clinical discussion with your peers around screening, diagnosis, and appropriate treatment strategies for a progressive ophthalmic condition.

DATE: Thursday, October 19, 2023

TIME: 6:15 PM

LOCATION: The Capital Grille 5197 Big Island Drive Jacksonville, FL 32246

OXERVATE® Case Exchange Registration

To reserve your seat, scan the QR code or visit:

https://www.pharmethodportal.com/dompe/register

Program Code: 10705

Hosted by: Haley Fowler

Email: katherine.fowler@dompe.com

Phone: 720/990-9962

A maximum of 8 attendees can register, so space may be limited.

Please plan to arrive 10-15 minutes early. Please be prepared to follow any state regulations related to Covid-19 safety.

I would like to take a moment to mention that as of January 1, 2022 in accordance with the PhRMA Code on Interactions with Health Care Professionals, Dompé will no longer pay for or provide alcohol in connection with speaker programs.

The information you provide will only be used to facilitate your attendance at the program. We look forward to your participation in this interactive discussion. Program attendance is by invitation only; we regret that this invitation cannot be forwarded.

oxervate® (cenegermin-bkbj ophthalmic solution) 0.002% (20 mcg/mL)

This is not a continuing medical education program. (CME)

Please see Important Safety Information on the next page and full Prescribing Information for OXERVATE at oxervate.com/prescribing-information.

Important Safety Information

oxervate® (cenegermin-bkbj ophthalmic solution) 0.002% (20 mcg/mL)

WARNINGS AND PRECAUTIONS

Use with Contact Lens

Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

Eye Discomfort

OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs.

ADVERSE REACTIONS

In clinical trials, the most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Other adverse reactions occurring in 1% to 10% of OXERVATE patients and more frequently than in the vehicle-treated patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation and tearing.

USE IN SPECIFIC POPULATIONS

Pregnancy

There are no data from the use of OXERVATE in pregnant women to inform any drug associated risks.

Lactation

The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for OXERVATE, and any potential adverse effects on the breastfed infant from OXERVATE.

Pediatric Use

The safety and effectiveness of OXERVATE have been established in the pediatric population. Use of OXERVATE in pediatric patients 2 years of age and older is supported by evidence from adequate and well-controlled trials of OXERVATE in adults with additional safety data in children.

INDICATION

OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) is indicated for the treatment of neurotrophic keratitis.

DOSAGE AND ADMINISTRATION

Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks.

To report ADVERSE REACTIONS, contact Dompé U.S. Inc. at 1-833-366-7387 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for OXERVATE at oxervate.com/prescribing-information.

US-OXE-2200025.2 04/22

Dompé